ClinicalTrials.gg
CompletedNCT03848208Updated Sep 17, 2020Results posted

A Single Dose-escalation Study of Cytisine in Adult Smokers

A Phase 1 interventional study of cytisine and placebo in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 1 site in Portugal. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-17.

Sponsored by Achieve Life Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.

Enrollment
13th of 22
74 · median 202
Started
2019
with 1 other
Phase 1
6 of 22
none open now
Registered
8th of 22
by date
Lead sponsor
10 of 22
Achieve Life Sciences

Among the 22 studies testing cytisine in Smoking Cessation, this one is the 13th largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 1, and was the 8th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cytisine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing cytisine in Smoking Cessation, or all of them as a file.
02

Study summary

The objectives of this study are:

  1. To assess the tolerability and safety of cytisine as a single oral dose.
  2. To define the Cmax levels associated to the occurrence of dose-limiting adverse events.
03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet ALL of the following criteria to be eligible for inclusion into the study:

  1. Free written prior to any procedure required by the study.
  2. Male or female subjects, age ≥18 years, at the time of signing the informed consent.
  3. Current daily cigarette smokers (averaging at least 10 cigarettes per day in the past 30 days).
  4. Expired air carbon monoxide (CO) ≥10 ppm.
  5. Able to swallow multiple tablets at one time.
  6. Able to fully understand, comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion into the study at screening.

  1. Known to cytisine or any of the .
  2. Known severe hypersensitivity to any other drug.
  3. Positive urinary drugs of abuse screen, determined within 28 days before cytisine/placebo dosing.
  4. Positive ethanol breath test.
  5. abnormal serum chemistry, hematology, coagulation or urinalysis values within 28 days of randomization (i.e. requiring treatment or monitoring).
  6. Clinically significant abnormalities in 12-lead echocardiogram () determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e. requiring treatment or further assessment).
  7. (BMI) classification for being underweight (\<18.5 kg/m2) or having ≥Class 2 obesity (≥35 kg/m2).
  8. History of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident, cardiac arrhythmia, or hospitalization for congestive heart failure.
  9. Blood pressure ≥160/100 mmHg, measured on the dominant arm, after at least 3 minutes in supine position.
  10. (CrCl) \<80 mL/min (estimated with the Cockroft-Gault equation).
  11. (ALT) or aspartate aminotransferase (AST) >2.0 x the (ULN).
  12. Any inability to comply with study restrictions (See Section 9)
  13. Any inability or difficulty in fasting.
  14. Difficulty in donating blood on either arm.
  15. If woman of , positive result in serum beta-human chorionic gonadotropin (hCG) pregnancy test.
  16. Women who are breast-feeding.
  17. Subjects who do not agree to use acceptable methods of during the study (See Section 9.4).
  18. Participation in a clinical study with an drug within the previous 2 months.
  19. Participation in more than 2 clinical trials within the previous 12 months.
  20. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

    Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion into the study at admission to each cohort.

  21. Any recent disease or condition or treatment that, according to the Investigator, would put the subject at undue risk due to study participation.
  22. Positive urinary drugs of abuse screen.
  23. Positive ethanol breath test.
  24. If female of childbearing potential, positive result in urine beta-hCG pregnancy test.
  25. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Cohort 1: Cytisine 6.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 1: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

  • Experimental
    Cohort 2: Cytisine 9.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 2: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

  • Experimental
    Cohort 3: Cytisine 12.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 3: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

  • Experimental
    Cohort 4: Cytisine 15.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 4: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

  • Experimental
    Cohort 5: Cytisine 18.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 5: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

  • Experimental
    Cohort 6: Cytisine 21.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 6: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

  • Experimental
    Cohort 7: Cytisine 24.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 7: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

  • Experimental
    Cohort 8: Cytisine 27.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 8: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

  • Experimental
    Cohort 9: Cytisine 30.0 mg

    Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: cytisine

  • Placebo comparator
    Cohort 9: Placebo

    Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

    Drug: placebo

Interventions

  • cytisine film-coated oral tablet

    Also known as: Tabex, cytisinicline

  • Drugplacebo

    matching placebo oral tablet

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation

    An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have to have a causal relationship with the treatment. A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; or is an important medical event which requires medical intervention to prevent one of the above. Treatment emergent events are those that occurred after the first dose of study drug.

    Time frame: From first dose of study drug through Day 6

  2. Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose

  3. Pharmacokinetics: Time to Occurrence of Cmax (Tmax)

    Time frame: Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose

07

Results

Posted Sep 17, 2020

Participant flow

Participants were enrolled in a single center in Portugal.

Participant flow — Overall Study
MilestonePlaceboCytisine 6 mgCytisine 9 mgCytisine 12 mgCytisine 15 mgCytisine 18 mgCytisine 21 mgCytisine 24 mgCytisine 27 mgCytisine 30 mg
Started18666666666
Completed18666666666
Not completed0000000000

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation

An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have to have a causal relationship with the treatment. A serious AE is any untoward medical occurrence or effect, that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; or is an important medical event which requires medical intervention to prevent one of the above. Treatment emergent events are those that occurred after the first dose of study drug.

Time frame:
From first dose of study drug through Day 6
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation
participantsPlaceboCytisine 6 mgCytisine 9 mgCytisine 12 mgCytisine 15 mgCytisine 18 mgCytisine 21 mgCytisine 24 mgCytisine 27 mgCytisine 30 mg
Any TEAE5214321224
Serious TEAE0000000000
TEAE Leading to Study Discontinuation0000000000
PrimaryPharmacokinetics: Maximum Observed Plasma Concentration (Cmax)
Time frame:
Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose
Reported as:
Mean · ng/mL
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)
ng/mLCytisine 6 mgCytisine 9 mgCytisine 12 mgCytisine 15 mgCytisine 18 mgCytisine 21 mgCytisine 24 mgCytisine 27 mgCytisine 30 mg
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)71.05 (56.07 to 86.03)93.62 (79.44 to 107.79)94.27 (74.87 to 113.66)126.45 (100.82 to 152.07)134.94 (107.00 to 162.88)150.08 (114.12 to 186.04)171.44 (149.31 to 193.57)151.05 (122.01 to 180.08)166.65 (120.95 to 212.34)
PrimaryPharmacokinetics: Time to Occurrence of Cmax (Tmax)
Time frame:
Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose
Reported as:
Median · hours
Pharmacokinetics: Time to Occurrence of Cmax (Tmax)
hoursCytisine 6 mgCytisine 9 mgCytisine 12 mgCytisine 15 mgCytisine 18 mgCytisine 21 mgCytisine 24 mgCytisine 27 mgCytisine 30 mg
Pharmacokinetics: Time to Occurrence of Cmax (Tmax)0.83 (0.50 to 2.00)1.38 (0.83 to 2.50)1.88 (1.25 to 2.50)1.88 (0.50 to 2.50)2.00 (1.50 to 3.00)1.89 (1.25 to 3.00)2.50 (0.83 to 3.00)2.75 (1.75 to 3.00)2.50 (1.00 to 3.00)

Adverse events

Collected over From first dose of study drug through Day 6. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/18 (0%)0/18 (0%)5/18 (27.8%)
Cytisine 6 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Cytisine 9 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Cytisine 12 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Cytisine 15 mg0/6 (0%)0/6 (0%)3/6 (50%)
Cytisine 18 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Cytisine 21 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Cytisine 24 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Cytisine 27 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Cytisine 30 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboCytisine 6 mgCytisine 9 mgCytisine 12 mgCytisine 15 mgCytisine 18 mgCytisine 21 mgCytisine 24 mgCytisine 27 mgCytisine 30 mg
NauseaGastrointestinal disorders2/181/61/62/61/62/60/62/60/61/6
VomitingGastrointestinal disorders0/181/60/60/60/61/60/61/60/62/6
PresyncopeNervous system disorders0/180/60/62/60/60/60/60/60/60/6
Abdominal painGastrointestinal disorders0/181/60/60/60/60/60/60/60/60/6
DiarrhoeaGastrointestinal disorders0/181/60/60/60/60/60/60/60/60/6
DyspepsiaGastrointestinal disorders0/180/60/60/61/60/60/60/60/60/6
FlatulenceGastrointestinal disorders0/180/60/60/60/60/60/60/60/61/6
Vessel puncture site haemorrhageGeneral disorders0/180/60/60/61/60/60/60/60/60/6
Oral herpesInfections and infestations0/180/60/61/60/60/60/60/60/60/6
Back painMusculoskeletal and connective tissue disorders2/180/60/60/60/60/60/60/61/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboCytisine 6 mgCytisine 9 mgCytisine 12 mgCytisine 15 mgCytisine 18 mgCytisine 21 mgCytisine 24 mgCytisine 27 mgCytisine 30 mgTotal
Mean31.3 ± 7.544.5 ± 12.135.7 ± 8.235.3 ± 11.134.7 ± 7.537.8 ± 12.930.3 ± 8.130.0 ± 5.530.3 ± 4.629.7 ± 8.933.5 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCytisine 6 mgCytisine 9 mgCytisine 12 mgCytisine 15 mgCytisine 18 mgCytisine 21 mgCytisine 24 mgCytisine 27 mgCytisine 30 mgTotal
Female1042232221028
Male824434445644
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCytisine 6 mgCytisine 9 mgCytisine 12 mgCytisine 15 mgCytisine 18 mgCytisine 21 mgCytisine 24 mgCytisine 27 mgCytisine 30 mgTotal
White1866566666671
Multiple Races00010000001
08

Study locations

1 site
  • BlueClinical
    Porto, 4250-449, Portugal
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Sep 2019, 6 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 34 phase 1 interventional studies under Smoking Cessation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 34. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2019
First posted
Feb 20, 2019
StartActual
Feb 28, 2019
Primary completionActual
Sep 12, 2019
CompletionActual
Sep 12, 2019
Results first posted
Sep 17, 2020
Last update
Sep 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03848208
Responsible party
Sponsor
First posted
Feb 20, 2019
Start date
Feb 28, 2019
Primary completion
Sep 12, 2019
Completion
Sep 12, 2019
Results posted
Sep 17, 2020
Last update
Sep 17, 2020

Study contacts

Marlene Fonseca, MD
principal investigator · Hospital da Prelada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion